Exactin: A specific inhibitor of Factor X activation by extrinsic tenase complex from the venom of *Hemachatus haemachatus*

4 5

1

⁶ Vallerinteavide Mavelli Girish^{*} and R. Manjunatha Kini^{*, §, ¶}

*Department of Biological Sciences, Faculty of Science, National University of
Singapore, Singapore 119260, Singapore, §Department of Biochemistry, Medical
College of Virginia, Virginia Commonwealth University, Richmond, Virginia
23298, USA, ¶University of South Australia, School of Pharmacy and Medical
Sciences, Adelaide, South Australia 5001, Australia.

13

14 Supplementary figures:





Fig. S1. Effect of pooled RP-HPLC fractions of peak 4 on prothrombin time. The fractions under each peak in RP-HPLC chromatogram (Fig.1B) were pooled and the effect of individual peaks on the prolongation of prothrombin time in human plasma was examined using a BBL fibrometer (Becton Dickinson and Co., Sparks, MD, USA). Only two pooled fractions (exactin peak denoted by *solid arrow* and peak denoted by *open arrow* in Fig.1B) prolonged the prothrombin time significantly in the plasma (>200 s at 0.2 mg/ml).

LEXYQKSKVVTXQPEQKFXYSDTTMFFPNHPVYLSGXTFSXTEEGNRRXXTTDKXNR



Α

Fig.S2. Reduction and pyridylethylation of exactin. (A) The complete sequence of exactin derived by Edman degradation with residues corresponding to cysteines denoted by 'X' (blank cycles corresponded to conserved cysteine residues in 3FTxs). (B) The ESI-MS of S-pyridylethylated exactin showing the four peaks of mass/charge (m/z) ratio ranging from +4 to +7 charges. The mass determined to be 7470.91 ± 1.6 Da corresponds to eight cysteine residues in the protein.





Fig.S3. Serine protease specificity of exactin. Exactin was screened against 10 serine 38 proteases: procoagulant serine proteases (FVIIa [300 nM], FXa [1 nM], FIXa [300 nM], FXIa 39 [0.125 nM], FXIIa [20 nM], α-thrombin [3 nM], kallikrein [1 nM]), anticoagulant serine 40 41 protease APC [2.5 nM] and fibrinolytic serine proteases (plasmin [3.6 nM], urokinase [40 units/ml] and t-PA [37 nM]). Exactin is a poor inhibitor with IC₅₀ values $>>300 \mu$ M when 42 compared to the inhibition to the full extrinsic tenase complex (ETC) [IC₅₀ 116 \pm 3.28 nM]. All 43 the experiments were done at 37°C. The hydrolysis of chromogenic substrates S-2222 (500 44 μM/FXa), S-2288 (500 μM/FVIIa; 1 mM/t-PA), S-2238 (250 μM/α-thrombin), S-2251 (1.2 45 mM/plasmin), S-2444 (0.3 mM/urokinase), S-2366 (0.67 mM/APC; 1 mM/FXIa), S-2302 (1 46 mM/FXIIa, kallikrein) and Spectrozyme FIXa (1 mM) were measured at 405 nm. Each data 47 point represents the average \pm SD of three independent experiments. 48



50

Fig.S4. Effect of exactin on FX activation by FVIIa in the absence of TF and phospholipids. A slight enhancement in FX activation was observed. Each data point represents the average of three independent experiments.

68 Supplementary tables:

S1.

FVIIa/TF/phospholipids

Kinetic parameters:

Table

69

70

Exactin (nM) Km (nM) Kcat (s⁻¹) Kcat/Km (s⁻¹ nM⁻¹) 0 14.57 ± 0.87 1.7 ± 0.017 0.117 ± 0.055 30 8.31 ± 0.72 0.95 ± 0.98 0.114 ± 0.008 100 6.46 ± 1.98 0.623 ± 0.2 0.095 ± 0.012 300 5.66 ± 1.9 0.32 ± 0.124 0.057 ± 0.013

Effect of exactin on FX activation

by

- 71
- 72
- 73
- 74
- 75
- 76

77 Table S2. Kinetic parameters: Effect of exactin on FX activation by FVIIa/phospholipids

Exactin (nM)	Km (nM)	Kcat (s ⁻¹)	Kcat/Km (s ⁻¹ nM ⁻¹)
0	36.56 ± 2.76	0.0558 ± 0.0046	0.0015 ± 0.00014
30	23.75 ± 2.71	0.0346 ± 0.0026	0.00145 ± 0.0002
100	18.37 ± 1.49	0.0262 ± 0.0035	0.00142 ± 0.0002
300	12.22 ± 1.029	0.0151 ± 0.0031	0.0013 ± 0.00026

78

Exactin (µM)	Km (µM)	Kcat (s ⁻¹)	Kcat/Km (s ⁻¹ µM ⁻¹)
0	1.03 ± 0.089	0.0017± 6.13 E-05	0.0016 ± 0.0001
100	0.76 ± 0.126	0.0011 ± 6.01 E-06	0.0014 ± 0.0002
300	0.42 ± 0.022	$0.0004 \pm 6.66 \text{ E-05}$	0.0009 ± 0.0002

80 Table S3. Kinetic parameters: Effect of exactin on FX activation by FVIIa/sTF

82 Table S4. Kinetic parameters: Effect of exactin on FIX activation by

83 FVIIa/TF/phospholipids

Exactin (µM)	Km (nM)	Kcat (s ⁻¹)	Kcat/Km (s ⁻¹ nM ⁻¹)
0	299.13 ± 7.84	1.34 ± 0.012	0.0044 ± 0.00015
10	231.83 ± 6.83	0.94 ± 0.0007	0.004 ± 0.0001
30	189±11.72	0.744 ± 0.018	0.0039 ± 0.00017
100	156.2 ± 2.74	0.353 ± 0.01	0.0022 ± 0.00006

84

85 Table S5. Kinetic parameters: Effect of exactin on FX activation by

86 FIXa/FVIIIa/phospholipids

Exactin (µM)	Km (nM)	Kcat (s ⁻¹)	Kcat/Km (s ⁻¹ nM ⁻¹)
0	4.31 ± 0.62	0.48 ± 0.064	0.11 ± 0.012
3	3.26 ± 0.46	0.07 ± 0.0024	0.021 ± 0.002
5	3.21 ± 0.24	0.042 ± 0.004	0.013 ± 0.002
10	3.23 ± 0.24	0.022 ± 0.004	0.007 ± 0.002

Exactin (µM)	Km (nM)	Kcat (s ⁻¹)	Kcat/Km (s ⁻¹ nM ⁻¹)
0	8.48 ± 1.06	0.85 ± 0.027	0.101 ± 0.01
3	8.49 ± 0.55	0.23 ± 0.044	0.0272 ± 0.006
5	9.19 ± 0.53	0.19 ± 0.023	0.021 ± 0.002
7	8.56 ± 0.32	0.15 ± 0.018	0.017 ± 0.0015

87 Table S6. Kinetic parameters: Effect of exactin on FX activation by RVV-X